GE Healthcare’s Alcyone Nuclear Cardiology Platform Goes Mainstream

 

September 9, 2011

September 9, 2011 — GE Healthcare announced it has received commitments from more than 100 customers globally for its Alcyone technology. The Alcyone is a nuclear cardiology platform designed to help facilitate workflow efficiency and dose management while maintaining image quality. It combines cadmium zinc telluride (CZT) detectors, focused pinhole collimation, stationary data acquisition and 3-D reconstruction.

Alcyone technology is available on both the Discovery NM 530c and the Discovery NM/CT 570c.  Its improvement in sensitivity and zero equipment motion may enable the potential for new clinical applications for 3-D dynamic acquisitions. It also offers the flexibility to manage patient dose more efficiently with up to four times lower injected dose.

In February 2011, GE completed the acquisition of the assets of Orbotech Medical Solutions Ltd. (OMS), a subsidiary of Orbotech Ltd. (Orbotech), and a manufacturer of the CZT detectors. 

The technology will be showcased with the Discovery NM 530c on display at the American Society of Nuclear Cardiology annual scientific session in Denver, Colo., Sept. 8-11, 2011.

For more information: www.gehealthcare.com

The content of this field is kept private and will not be shown publicly.
By submitting this form, you accept the Mollom privacy policy.